<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201146</url>
  </required_header>
  <id_info>
    <org_study_id>2009L03464</org_study_id>
    <nct_id>NCT03201146</nct_id>
  </id_info>
  <brief_title>Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC</brief_title>
  <official_title>A Phase 1/2 Study of Apatinib in Combination With AP(Pemetrexed/Cisplatin) or AC(Pemetrexed/Carboplatin) as First-line Chemotherapy for Advanced Epidermal Growth Factor Receptor(EGFR) Wild Type Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical activity of Apatinib in&#xD;
      combination with AP(Pemetrexed/Carboplatin) or AC(Pemetrexed/Carboplatin) as first-line&#xD;
      chemotherapy in subjects with advanced EGFR wild type non-squamous non-small cell lung&#xD;
      cancer(NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apatinib, an oral highly potent tyrosine-kinase inhibitor targeting VEGFR-2, has demonstrated&#xD;
      improved survival in previously treated patients with advanced non-small-cell lung&#xD;
      cancer(NSCLC).&#xD;
&#xD;
      The phase I study is conducted to explore the safety, tolerability, dose-limiting&#xD;
      toxicities(DLT), Maximum Tolerable Dose(MTD), and preliminary anti-tumor activity of Apatinib&#xD;
      combined with platinum-based doublet chemotherapy(PB-DC) in first-line advanced EGFR wild&#xD;
      type non-squamous non-small cell lung cancer. This will use a dose reduction trial design. A&#xD;
      cohort of 3~6 subjects will be enrolled at each dose level, If 0 of 3 or ≤ 1 of 6 subjects&#xD;
      experience a DLT, the phase I trial will stop and the current dose will be considered the&#xD;
      MTD. If 1 of 6 or more subjects experiences a DLT, dose reduce to the next dose will occur.&#xD;
&#xD;
      Following completion of the dose de-escalation trial and determination of MTD, A randomized&#xD;
      controlled trial(RCT) including 30 subjects may be enrolled to further evaluate safety,&#xD;
      tolerability, and preliminary anti-tumor activity of Apatinib in combination with&#xD;
      platinum-based doublet chemotherapy(PB-DC) in the same target population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>To determine ORR of Apatinib in combination with AP or AC in subjects with advanced EGFR wild type non-squamous non-small cell lung cancer. ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median Overall Survival</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>median Overall survival is defined as the time in months from the start of protocol treatment until the date of death, or the date of last follow-up if alive. Kaplan-Meier methods will be used to estimate overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year Overall Survival Rate</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Kaplan Meier methods were used to estimate the 1-year survival probabilities for time to death from any cause. Estimates of the 1-year (365 day) survival probabilities and corresponding 95% confidence intervals (CI) were presented by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Combination Chemotherapy</condition>
  <condition>Apatinib</condition>
  <arm_group>
    <arm_group_label>Apatinib 750mg + AP or AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib 500mg + AP or AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib 250mg + AP or AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AP or AC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum-based doublet chemotherapy, as the control group in the phase 2 study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Doses to be determined following the completion of Phase I of the study.</description>
    <arm_group_label>Apatinib</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP or AC</intervention_name>
    <description>Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.</description>
    <arm_group_label>AP or AC</arm_group_label>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_label>Apatinib 250mg + AP or AC</arm_group_label>
    <arm_group_label>Apatinib 500mg + AP or AC</arm_group_label>
    <arm_group_label>Apatinib 750mg + AP or AC</arm_group_label>
    <other_name>Pemetrexed/Cisplatin or Pemetrexed/Carboplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib 250mg</intervention_name>
    <description>250mg/d,q.d.,p.o.every 21 days.</description>
    <arm_group_label>Apatinib 250mg + AP or AC</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib 500mg</intervention_name>
    <description>500mg/d,q.d.,p.o.every 21 days.</description>
    <arm_group_label>Apatinib 500mg + AP or AC</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib 750mg</intervention_name>
    <description>750mg/d,q.d.,p.o.every 21 days.</description>
    <arm_group_label>Apatinib 750mg + AP or AC</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Signed the informed consent form prior to patient entry.&#xD;
&#xD;
          -  2. ≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          -  3. Histologically or pathologically confirmed non-squamous EGFR wild-type,&#xD;
             ALK-rearrangement negative, stage IV non-small cell lung cancer(NSCLC).&#xD;
&#xD;
          -  4. Must have at least one measurable lesion as per RECIST 1.1 defined as a lesion that&#xD;
             is 10mm in longest diameter or lymph node that is 15mm in short axis imaged by CT&#xD;
             scan, prior topical treatment, such as radiotherapy or cryosurgery to the lesions is&#xD;
             not allowed.&#xD;
&#xD;
          -  5. No prior systemic chemotherapy for advanced or metastatic NSCLC.&#xD;
&#xD;
          -  6. Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  7. Life expectancy of more than 3 months.&#xD;
&#xD;
          -  8. Adequate bone marrow function : WBC ≥ 3.0 ×10 E+9/L, neutrophil ≥ 1.5 × 10 E+9/L,&#xD;
             platelets ≥ 80 × 10E+9/L,Hb ≥ 10.0g/dL.&#xD;
&#xD;
          -  9. Adequate hepatic and renal functions: a total bilirubin (TBil) of ≤1.5 upper normal&#xD;
             limitation (UNL), a alanine aminotransferase (ALAT) and aspartate aminotransferase&#xD;
             (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis, a creatinine (Cr) of ≤ 1.5&#xD;
             UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault).&#xD;
&#xD;
          -  10. With normal coagulation function: INR and PTT, each ≤ 1.5 x ULN.&#xD;
&#xD;
          -  11. Adequate cardiovascular function: left ventricular ejection fraction (LVEF) ≥ 50%,&#xD;
             QTcF ≤ 450 msec.&#xD;
&#xD;
          -  12. Alkaline phosphatase ≤ 2.5 x ULN.&#xD;
&#xD;
          -  13. The subjects are willing to coordinate with the follow-up with good compliance.&#xD;
&#xD;
          -  14. Female subjects of child-bearing potential must agree to use contraceptive&#xD;
             measures starting 1 week before the administration of the first dose of apatinib until&#xD;
             8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive&#xD;
             measures during the study and 8 weeks after last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with active brain metastasis, carcinomatous meningitis, or spinal&#xD;
             compression, or disease of brain or pia mater according to the screening test,&#xD;
             imaging, CT or MRI tests (patients who have completed the treatment and in a stable&#xD;
             condition 21 days before screening could be included, but brain MRI, CT or venography&#xD;
             is required to confirm that there are no brain hemorrhage symptoms).&#xD;
&#xD;
          -  2. Patients with uncontrollable hypertension (systolic blood pressure&gt; 140 mmHg,&#xD;
             diastolic blood pressure&gt; 90 mmHg, despite optimal drug therapy).&#xD;
&#xD;
          -  3. Patients with with grade Ⅱ myocardial ischemia or myocardial infarction, poor&#xD;
             control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms).&#xD;
&#xD;
          -  4. According to NYHA standard, grade Ⅲ ~ Ⅳ heart failure, or cardiac color Doppler&#xD;
             ultrasound examination showed left ventricular ejection fraction (LVEF) &lt;50%.&#xD;
&#xD;
          -  5. Coagulation dysfunction (INR&gt; 1.5, PT&gt; ULN +4s or APTT&gt; 1.5 ULN), with bleeding&#xD;
             tendency or ongoing thrombolysis or anti-blood coagulation treatment.&#xD;
&#xD;
          -  6. Patients treated with anticoagulation agents or Vitamin K antagonist such as&#xD;
             Warfarin, heparin, or other similar drugs.&#xD;
&#xD;
          -  7. Patients who had obvious hemoptysis within 2 months before screening, or&#xD;
             experienced daily hemoptysis with a volume more than half a tea spoon (2.5ml) or&#xD;
             above.&#xD;
&#xD;
          -  8. Patients who experienced bleeding symptoms of clinical significance within 3 months&#xD;
             before screening, or with confirmed bleeding tendency such as hemorrhage of digestive&#xD;
             tract, hemorrhagic gastric ulcer, baseline occult blood in stool ++ and above, or&#xD;
             vasculitis, etc.&#xD;
&#xD;
          -  9. Patients who manifested arterial/venous thrombus events, e.g. cerebrovascular&#xD;
             accident (including transient ischemic attack), deep venous thrombosis and pulmonary&#xD;
             embolism, etc., within 12 months before screening.&#xD;
&#xD;
          -  10. Known genetic or acquired bleeding or bleeding tendency (such as hemophilia, blood&#xD;
             coagulation dysfunction, thrombocytopenia, and hypersplenism, etc.).&#xD;
&#xD;
          -  11. Patients who have unhealed wounds or fractures for a long time.&#xD;
&#xD;
          -  12. Patients who received major surgical operations or experienced severe traumatic&#xD;
             injuries, bone fracture, or ulcers within 4 weeks before screening.&#xD;
&#xD;
          -  13. Patients with obvious factors affecting absorption of oral drugs, such as&#xD;
             difficulties in swallowing, chronic diarrhea and intestinal obstruction, etc.&#xD;
&#xD;
          -  14. Occurrence of abdominal fistula, gastrointestinal perforation, or intraperitoneal&#xD;
             abscess within 6 months before screening.&#xD;
&#xD;
          -  15. Patients whose routine urine tests indicate that urine protein ≥ ++ or verifies&#xD;
             that the 24-h urine protein quantitation ≥ 1.0 g.&#xD;
&#xD;
          -  16. Patients with active hepatitis B virus or hepatitis c virus infection.&#xD;
&#xD;
          -  17. Active infection requiring antimicrobial treatment, such as antibacterial,&#xD;
             antifungal, or antiviral therapy.&#xD;
&#xD;
          -  18. Patients with clinical symptoms, or dropsy of serous cavity requiring surgical&#xD;
             treatment (including hydrothorax, ascites, and hydropericardium).&#xD;
&#xD;
          -  19. Patients who have a history of psychotropic drug abuse and are unable to break the&#xD;
             habit, or who have a psychogeny.&#xD;
&#xD;
          -  20. Patients who have taken part in other drug clinical tests within 4 weeks before&#xD;
             screening.&#xD;
&#xD;
          -  21. Prior VEGFR inhibitor treatment.&#xD;
&#xD;
          -  22. Patients who formerly suffered from or currently are complicated with other&#xD;
             uncured malignant tumors, except basal cell carcinoma, carcinoma in situ of cervix and&#xD;
             superficial bladder cancer that have been cured.&#xD;
&#xD;
          -  23. Patients who received the treatment with potent CYP3A4 inhibitors within 7 days&#xD;
             before screening, or potent CYP3A4 inducers within 12 days before being included.&#xD;
&#xD;
          -  24. Pregnant or lactating women, fertile patients who are unwilling or unable to take&#xD;
             effective contraceptive measures.&#xD;
&#xD;
          -  25. Conditions determined by investigators to possibly affect the clinical study or&#xD;
             determination of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>You Lu, MD</last_name>
    <phone>86-028-85422114</phone>
    <email>radyoulu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meijuan Huang, MD</last_name>
    <phone>86-028-85422114</phone>
    <email>hmj107@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>You Lu, MD</last_name>
      <phone>86-028-85422114</phone>
      <email>radyoulu@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Meijuan Huang, MD</last_name>
      <phone>86-028-85422114</phone>
      <email>hmj107@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, Zheng C, Zuo Y. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010 Oct 5;10:529. doi: 10.1186/1471-2407-10-529.</citation>
    <PMID>20923544</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>June 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>You Lu,MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

